澳大利亚宫颈癌消除的预计时间框架:一项建模研究
该建模研究使用Policy1-Cervix动态模型,估计澳大利亚在维持高覆盖率HPV疫苗接种和筛查的情况下,宫颈癌年龄标化发病率可在2020年前后降至每10万女性6例以下,2028年前后降至4例以下,并估计死亡率在2034年前后降至每10万女性1例以下。
要点
- 若维持高覆盖率接种与筛查,澳大利亚宫颈癌年发病率预计2020年(范围2018-22)降至每10万女性6例以下。
- 发病率预计2028年(范围2021-35)降至每10万女性4例以下,可作为消除阈值。
- 宫颈癌死亡率预计2034年(范围2025-47)降至每10万女性1例以下。
核心结论
- 若维持高覆盖率疫苗接种和筛查,以每年每10万女性4例新发为消除阈值,澳大利亚有望在未来20年内将宫颈癌作为公共卫生问题消除。
- 此后仍需维持筛查和疫苗接种以保持极低的宫颈癌发病率和死亡率。
研究设计与样本
- 建模研究,使用经过广泛验证的Policy1-Cervix动态模型,估计澳大利亚2015至2100年宫颈癌年龄标化发病率。
- 模型纳入女孩HPV疫苗年龄别覆盖率(含补种)、2013年男孩纳入疫苗项目、2018年从四价转为九价疫苗以及转为HPV初筛的影响。
- 考虑两种未来筛查情景:已或将要接种九价疫苗的队列继续每5年HPV筛查,或不提供筛查。
主要发现
- 澳大利亚宫颈癌年龄标化年发病率预计2020年(范围2018-22)降至每10万女性6例以下,2028年(范围2021-35)降至4例以下。
- 到2066年(范围2054-77),若已接种九价疫苗队列继续每5年HPV筛查,发病率降至并保持在每10万女性1例以下;若这些队列不筛查,则降至3例以下。
- 宫颈癌死亡率预计2034年(范围2025-47)降至年龄标化年率每10万女性1例以下,即使未来筛查仅提供给未接种九价疫苗的老年队列。
- 达到上述率值的具体年份取决于年龄标化所用人群、HPV筛查行为和检测特征、男性接种对女性群体免疫的增量效应以及未来良性子宫切除术频率的假设。
关键数值与推荐
- 当前澳大利亚宫颈癌年龄标化发病率为每10万女性7例。
- 潜在消除阈值:罕见癌症阈值每10万女性6例新发,或较低阈值每10万女性4例新发。
- 筛查方案:25-69岁女性每5年HPV初筛,70-74岁女性退出检测。
临床怎么用
- 维持高覆盖率HPV疫苗接种和筛查是使宫颈癌发病率降至消除阈值以下的关键。
- 即使发病率降至消除阈值,仍需持续维持筛查和疫苗接种以保持低发病率和死亡率。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2007, Australia was one of the first countries to introduce a national human papillomavirus (HPV) vaccination programme, and it has since achieved high vaccination coverage across both sexes. In December, 2017, organised cervical screening in Australia transitioned from cytology-based screening every 2 years for women aged from 18-20 years to 69 years, to primary HPV testing every 5 years for women aged 25-69 years and exit testing for women aged 70-74 years. We aimed to identify the earliest years in which the annual age-standardised incidence of cervical cancer in Australia (which is currently seven cases per 100 000 women) could decrease below two annual thresholds that could be considered to be potential elimination thresholds: a rare cancer threshold (six new cases per 100 000 women) or a lower threshold (four new cases per 100 000 women), since Australia is likely to be one of the first countries to reach these benchmarks. METHODS: In this modelling study, we used Policy1-Cervix-an extensively validated dynamic model of HPV vaccination, natural history, and cervical screening-to estimate the age-standardised incidence of cervical cancer in Australia from 2015 to 2100. We incorporated age-specific coverage of the Australian National HPV Vaccination Program in girls, including the catch-up programme, and the inclusion of boys into the vaccine programme from 2013, and a change from the quadrivalent to the nonavalent vaccine from 2018. We also modelled the effects of the transition to primary HPV screening. We considered two scenarios for future screening recommendations regarding the cohorts who will be and who have been offered the nonavalent vaccine: either that HPV screening every 5 years continues, or that no screening would be offered to these women. FINDINGS: We estimate that, in Australia, the age-standardised annual incidence of cervical cancer will decrease to fewer than six new cases per 100 000 women by 2020 (range 2018-22), and to fewer than four new cases per 100 000 women by 2028 (2021-35). The precise year of attaining these rates is dependent on the population used for age-standardisation, HPV screening behaviour and test characteristics, the incremental effects of vaccination of men on herd immunity in women, and assumptions about the future frequency of benign hysterectomies. By 2066 (2054-77), the annual incidence of cervical cancer will decrease and remain at fewer than one case per 100 000 women if screening for HPV every 5 years continues for cohorts who have been offered the nonavalent vaccine, or fewer than three cases per 100 000 women if these cohorts are not screened. Cervical cancer mortality is estimated to decrease to less than an age-standardised annual rate of one death per 100 000 women by 2034 (2025-47), even if future screening is only offered to older cohorts that were not offered the nonavalent vaccine. INTERPRETATION: If high-coverage vaccination and screening is maintained, at an elimination threshold of four new cases per 100 000 women annually, cervical cancer could be considered to be eliminated as a public health problem in Australia within the next 20 years. However, screening and vaccination initiatives would need to be maintained thereafter to maintain very low cervical cancer incidence and mortality rates. FUNDING: National Health and Medical Research Council (Australia).
引用
- Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2018. PMID: 30291040. doi:10.1016/S2468-2667(18)30183-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。